Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korean National Health Insurance Covers Novartis Galvus In Second-Line Type 2 Diabetes

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Novartis Korea's DPP-4 inhibitor type 2 diabetes treatment Galvus (vildagliptin) will be covered by South Korea's National Health Insurance Policy beginning Feb. 1 for second-line treatment

You may also be interested in...



Roche Is Latest MNC To Partner A Primary Care Product In Korea

Handok, which is partially owned by Sanofi, will sell Roche’s Madopar for Parkinson’s disease in Korea.

Emerging Market Outlook: PharmAsia News Earnings Call Roundup

In a new feature, PharmAsia News takes a look at the earnings calls for some of the major pharma companies and what they are saying about Asia Pacific and emerging markets

Emerging Market Outlook: PharmAsia News Earnings Call Roundup

In a new feature, PharmAsia News takes a look at the earnings calls for some of the major pharma companies and what they are saying about Asia Pacific and emerging markets

UsernamePublicRestriction

Register

SC070983

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel